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A B S T R A C T
Fluconazole resistance among Cryptococcus neoformans is unusual in post-transplantation patients.
Voriconazole is a triazole agent with good antifungal activity but also with drug–drug interactions
because of potent inhibition of the P450 enzyme system. The interaction with immunosuppressive
agents, especially calcineurin inhibitors, is of concern in post-transplantation patients. We report the
ﬁrst case of ﬂuconazole-resistant cryptococcal meningitis in a kidney transplant recipient successfully
treated with voriconazole, but complicated with a raised serum concentration of tacrolimus and
hyponatremia after co-administration. A 43-year-old man with a history of renal transplantation and on
long-term immunosuppressive agents, including mycophenolate and tacrolimus, suffered from
recurrent cryptococcal meningitis. He was treated with amphotericin B-liposome for 24 days because
of ﬂuconazole resistance. However, cryptococci were still found in the cerebrospinal ﬂuid; oral
voriconazole was substituted. Six days after co-administration of voriconazole and tacrolimus, the
trough concentration of tacrolimus markedly increased and hyponatremia developed. A culture of the
CSF did not yield growth of Cryptococcus. Conditions improved after the cessation of tacrolimus for three
days followed by reducing the dosage of voriconazole and tacrolimus. When voriconazole is initially
added, the dosage of tacrolimus should be reduced. Close monitoring of tacrolimus concentration and its
adverse effects, including nephrotoxicity, hyperglycemia, hyperkalemia, and hyponatremia, are
mandatory.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Although fungal infections are not uncommon complications
among post-transplantation patients on long-term immunosup-
pressive therapy, resistance to ﬂuconazole among Cryptococcus
neoformans is unusual in these patients. They are difﬁcult to treat
not only because of their immunocompromised status, but also
because of the pharmacokinetic/pharmacodynamic properties of
the antifungal agents. Voriconazole is a triazole with a broad
spectrum of antifungal activity. Similar to other azoles, voricona-
zole is metabolized by the cytochrome P450 (CYP) enzyme system
and is known to inhibit CYP 2C19, 2C9, and 3A4,1 which is also
involved in the metabolism of calcineurin inhibitors, such as* Corresponding author. Tel.: +886 6 235 3535x3596; fax: +886 6 275 2038.
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doi:10.1016/j.ijid.2009.04.012tacrolimus.2,3 We describe a patient with ﬂuconazole-resistant
cryptococcal meningitis who was successfully treated with
voriconazole but complicated with a raised serum concentration
of tacrolimus after co-administration.
2. Case report
A 43-year-old man, weighing 47 kg, had a history of hyperten-
sion and had received a renal transplantation in India ten years
earlier. Immunosuppressive agents including mycophenolate
360 mg/day, tacrolimus 2 mg/day, and methylprednisolone
4 mg/day were continued for more than ﬁve years. In the past
two years, the patient had been admitted four times because of
recurrent cryptococcal meningitis due to incomplete course of
treatment. Several days previously, he had suffered from nausea,
vomiting, fever, and neck stiffness, which revealed signs of
increased intracranial pressure. Recurrent meningitis was sus-
pected at the outpatient clinic but the patient refused admission.ses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Concentrations of tacrolimus in a patient receiving voriconazole.
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dizziness with severe vomiting.
On admission, his vital signs were normal. The hemogram
disclosed a hemoglobin level of 11.7 g/dl (normal 13.5–17.0 g/dl)
and leukocyte count of 8.7  109/l (normal 3.4–9.1  109/l), with
91% segments, 3% band forms, and 3.2% lymphocytes. Serum
biochemical valueswere: blood urea nitrogen 31 mg/dl (normal 7–
21 mg/dl), creatinine 2.1 mg/dl (normal 0.7–1.5 mg/dl), aspartate
aminotransferase 21 U/l (normal 5–40 U/l), alanine aminotrans-
ferase 19 U/l (normal 5–55 U/l), sodium 132 mmol/l (normal 135–
155 mmol/l), and potassium 4.9 mmol/l (normal 3.5–5.5 mmol/l).
A lumbar puncturewas performed and the initial pressurewas 178
mmH2O. Analysis of the cerebrospinal ﬂuid (CSF) revealed
pleocytosis (white blood cell (WBC) count 50  106/l, 54%
lymphocytes), low glucose level (17 mg/dl), high protein level
(81 mg/dl), positive Indian ink, and raised titer of cryptococcal
antigen (titer 1:1024). A culture of CSF yielded growth of C.
neoformans. Magnetic resonance imaging of the brain did not show
any abnormalities.
Fluconazole 200 mg/day was administered from admission but
was switched to amphotericin B-liposome (AmBisome1; Gilead)
4 mg/kg/day because of ﬂuconazole resistance, from day 2 to day
25 of his hospitalization. By E-test diffusion (AB Biodisk, Solna,
Sweden), the minimum inhibitory concentrations of ﬂuconazole,
voriconazole, and amphotericin B were >256, 0.5, and 0.123 mg/
ml, respectively. However, cryptococci were still found in the CSF.
Therefore, oral voriconazole 800 mg/day was substituted for
amphotericin B-liposome from day 25. Meanwhile, the tacrolimus
level was within the therapeutic range (9.9 ng/ml, aimed
therapeutic interval 5–15 ng/ml). Six days later, nausea and
vomiting were noted and the tacrolimus level markedly increased
(28.5 ng/ml). Renal functions remained at the baseline levels
(blood urea nitrogen 33 mg/dl, creatinine 2.1 mg/dl). The sodium
level decreased to 122 mmol/l and a low cortisol level was noted
(1.22mg/ml, normal 6–28 mg/ml). A culture of the CSF performed
on day 31 did not yield growth of Cryptococcus. Voriconazole was
withdrawn on day 32, and amphotericin B-liposomewas resumed.
Tacrolimus was completely discontinued for three days and then
the daily dose was reduced to 0.5 mg. Trough levels of tacrolimus
were 14.8 ng/ml and 6.5 ng/ml on days 33 and 38, respectively
(Figure 1). On day 37, a decreased dosage of voriconazole 600 mg/
day was prescribed again in place of amphotericin B-liposome.
Serial follow-up concentrations of tacrolimus were within the
therapeutic range thereafter. The patient’s condition was stable
and he was discharged on day 53. After discharge, he received oral
voriconazole for additional ﬁve months and no cryptococcosis
recurred during follow-up visit.
3. Discussion
According to the Infectious Diseases Society of America
guidelines, amphotericin B plus ﬂucytosine for 2 weeks and then
ﬂuconazole for a minimum 10 weeks is recommended in non-
HIV-infected patients.4 For our patient, culture of the CSFyielded growth of ﬂuconazole-resistant C. neoformans, and
response to amphotericin B liposome was unsatisfactory
because cryptococci were still found in the CSF. In addition,
in spite of less nephrotoxicity than conventional amphotericin B,
elevations of serum creatinine have occurred in 10–30% of
transplant patients treated with amphotericin B liposome.5
Voriconazole was the alternative choice for our patient, since
previous studies have shown that voriconazole is effective in
patients with ﬂuconazole-resistant fungal infections and those
who have failed standard antifungal therapy.6 Resistance to
ﬂuconazole among C. neoformans is unusual in HIV-negative
patients.7 So far as we know, the case described here is the ﬁrst
case of ﬂuconazole-resistant cryptococcal meningitis success-
fully treated with voriconazole after failure of amphotericin B in
a post-transplantation patient.
In a randomized, two-treatment, placebo-controlled pharma-
cokinetic study in liver transplant recipients, the tacrolimus (2 mg/
day) trough blood concentration increased 10-fold in patients who
received voriconazole on day 5.8 When voriconazole is initiated,
the manufacturer recommends that the concurrent tacrolimus
dose be reduced by one-third.9 However, there are some case
reports that have shown a requirement for an 80–90% reduction in
maintenance dosage of tacrolimus.2,3,10 In our case, nausea and
vomiting occurred after co-administration for six days. The
tacrolimus dosage was reduced by half and voriconazole was
reduced by one-fourth. Such a rapid-onset interaction is clinically
important and clinicians should monitor tacrolimus levels daily
when voriconazole is co-administered.
The major adverse effects of tacrolimus include nephrotoxicity,
hyperglycemia, and hyperkalemia.11 A previous study has reported
that hyponatremia and hyperkalemia are more frequent in renal
transplant recipients treated with tacrolimus than with cyclos-
porin for the ﬁrst 90 days.11 In our case, obvious nephrotoxicity
and hyperkalemia were not present, but hyponatremia was noted.
Although adrenal insufﬁciency was also considered as one of the
causes of hyponatremia, reducing levels of sodium progressed only
when the tacrolimus level increased. The association between
raised tacrolimus level and worsening hyponatremia was more
favored. Hyponatremia caused by the syndrome of inappropriate
secretion of antidiuretic hormones during administration of
tacrolimus has been reported.12 Another study reported a case
of sodium-losing nephropathy thatwas associatedwith tacrolimus
administration, and symptoms improved after the cessation of
tacrolimus.13 Whether raised tacrolimus levels lead to further loss
of sodium needs to be conﬁrmed in the future.
In conclusion, ﬂuconazole resistance should be considered
among post-transplantation patients with recurrent cryptococcal
meningitis. Voriconazole is an alternative choice but co-admin-
istration of tacrolimus and voriconazole may result in a
signiﬁcantly increased concentration of tacrolimus. When vor-
iconazole is used, the concentration of tacrolimus should be closely
monitored. Clinicians should also be alert to the adverse effects of
tacrolimus, including nephrotoxicity, hyperglycemia, hyperkale-
mia, and hyponatremia.
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